公开(公告)号：US20240123034A1

公开(公告)日：2024-04-18

申请号：US17768514

申请日：2020-10-15

Applicant: ModernaTX, Inc. ,  BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

Inventor： Eric Yi-Chun Huang ,  Jared Iacovelli ,  Seymour De Picciotto ,  Sze-Wah Tse ,  Laurie Kenney ,  Katherine Olson ,  Howard Gendelman ,  Lee R. Mosley

IPC: A61K38/19 ,  A61K9/51 ,  A61K31/7115 ,  A61P25/16

CPC classification number: A61K38/193 ,  A61K9/5123 ,  A61K31/7115 ,  A61P25/16

Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising mRNA molecules encoding human granulocyte macrophage colony stimulating factor (GM-CSF) polypeptides and uses thereof in the treatment of Parkinson's Disease. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding human GM-CSF for use in such treatment.

公开(公告)号：US20230130155A1

公开(公告)日：2023-04-27

申请号：US17759687

申请日：2021-01-29

Applicant: ModernaTX, Inc.

Inventor： Eric Yi-Chun Huang ,  Sze-Wah Tse ,  Seymour De Picciotto ,  Laurie Kenney

IPC: A61K9/51 ,  A61K31/7105 ,  B82Y5/00 ,  A61P37/06

Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising metabolic reprogramming molecules and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding metabolic reprogramming polypeptides, e.g., IDO, TDO, AMPK, AhR, ALDH1A2, HMOX1, CD73 or CD39. The LNP compositions of the present disclosure can reprogram myeloid and/or dendritic cells, suppress T cells and/or induce immune tolerance in vivo.

公开(公告)号：US20250041393A1

公开(公告)日：2025-02-06

申请号：US18706652

申请日：2022-11-01

Applicant: MODERNATX, INC.

Inventor： Eric Yi-Chun Huang ,  Paul Stein ,  Laurie Kenney ,  Michelle Dutra ,  Myoungjoo Kim ,  Pranitha Vangala

IPC: A61K39/00 ,  A61K9/127 ,  A61K9/51 ,  A61P37/06 ,  G01N33/50

Abstract: The disclosure features lipid nanoparticle (LNP) compositions ITB6 molecules and uses thereof. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding ITB6 polypeptides. The LNP compositions of the present disclosure can reprogram dendritic cells, suppress T cells and/or induce immune tolerance in vivo.